GG Biotech Intel

Key Thesis — PM Pathway & HD/Gene Therapy

PM pathway is being framed as an ultra-rare "Baby KJ" lane to move bespoke gene-editing from one-off INDs toward approvable/reimbursable, repeatable platform economics, but it likely does not change outcomes for HD/gene therapy programs where FDA thinks efficacy still isn't established. Tracked names: QURE RGNX

Leadership/Election: Expect cabinet-level stability into midterms with RFK viewed as electorally useful and additional HHS "guardrails" installed via Oz/CMS-linked staff.
Prasad: Mike continues to treat Prasad as de facto "co-commissioner" behind multiple investor-shocking calls, with Moderna flu RTF and prior Sarepta DMD actions cited as unusual White House override moments.
Visibility: Prasad remains employed but has gone lower-profile and was absent from recent FDA initiative rollouts where he previously would have been featured.
Predictability Risk: Even if Prasad exits, churn in center leadership is the bigger structural problem because it makes prior FDA guidance less bankable.
PM Pathway Mechanics: PM evolved from "mechanism-as-evidence" rhetoric into an ultra-rare/single-patient mutation construct and this week moved from journal-article talk into draft guidance that staff/sponsors can actually cite.
PM Scope: FDA says it could apply beyond N=1 mutations, but Mike flagged ongoing confusion on whether that's truly new versus codifying existing flexibility for "dramatic effect" therapies.
CNBC Makary/QURE: Mike said Makary's CNBC comments sounded consistent with the uniQure HD situation where FDA effectively reset prior guidance and wants additional study, implying Makary is not dissenting from that posture.
OTC Switches: Makary keeps floating OTC as a pricing lever but Mike hasn't heard the agency plans to force switches against sponsor preference.
Drug Pricing: MFN-style deals have worked politically so far and haven't visibly impaired profits yet, but may create longer-term precedent and reinforce CEO-to-White House access as a new policy lever.

⚖

Regulatory Updates

Timeline of FDA actions, PM pathway evolution, and regulatory posture shifts impacting QURE, RGNX, and gene therapy names.

View Timeline →

▲

Market Movers

SMID/small-cap biotech tape reads. What moved, why, and what the positioning tells you. Updated daily.

Read Tape →

📅

FDA Calendar

Upcoming PDUFA dates, AdCom meetings, and conference catalysts with timeline and context.

View Calendar →

🔬

Pipeline Tracker

Deep dives on key names: KRYS commercial trajectory, CF catalyst, and positioning frameworks.

Track Names →

Phase 3 COMP006 hit primary in TRD. MADRS Δ -3.8 (p<0.001). Requested FDA meeting for rolling NDA. Classic approval-probability repricing + short cover.

SOL-1 Phase 3 superiority in wet AMD met. Control arm better than feared, delta wasn't the knockout. Next: Macula Society Feb 25–28.

FDA declined national priority voucher route. Traditional path preferred by market—slower, cleaner, less "accelerated approval" knife fight.

Feb

21

VNDA Vanda

Bysanti

Bipolar I / Schizophrenia

Feb

25

ETON Eton

ET-600

—

Feb

28

BMRN BioMarin

Palynziq

PKU (adolescents)

Feb

28

ASND Ascendis

TransCon CNP

Achondroplasia (peds)

Biotech Policy & Regulatory Intel

Raw Intel Notes

Intel Desks

Top Movers Snapshot

Upcoming PDUFAs